Acro Biomedical (ACBM) FCF Margin (2017 - 2022)

Acro Biomedical's FCF Margin history runs 6 years deep, the most recent figure standing at 2.94% for Q4 2022.

• In Q4 2022, FCF Margin rose 718.0% year-over-year to 2.94%; the TTM figure through Sep 2023 stood at 3.72% (up 1830.0% YoY), while the FY2022 annual figure was 22.4%, down 4739.0% from the prior year.
• FCF Margin was 2.94% for Q4 2022 at Acro Biomedical, down from 87.82% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 87.82% in Q1 2022 to a low of 23.3% in Q2 2018.
• Historically, FCF Margin has averaged 16.13% across 5 years, with a median of 0.17% in 2018.
• The sharpest annual moves came in 2021 and 2022: FCF Margin sank 464 bps in 2021, then soared 9624 bps in 2022.
• A 5-year view of FCF Margin shows it stood at 12.88% in 2018, then surged by 40 bps to 18.05% in 2019, then slumped by 121 bps to 3.78% in 2020, then sank by 168 bps to 10.12% in 2021, then surged by 71 bps to 2.94% in 2022.
• The last three FCF Margin figures came in at 2.94% (Q4 2022), 87.82% (Q1 2022), and 10.12% (Q4 2021), per Business Quant data.